Ilivia Neo 7 DR-T 429529; Intica Neo 7 DR-T 429558; Intica Neo 5 DR-T 429568
Biotronik, Inc. · Decision date Sep 25, 2026
What did the FDA approve?
Biotronik, Inc. received an FDA approval decision dated 2026-09-25 for three devices listed under PMA supplement P000009/S124: Ilivia Neo 7 DR-T 429529, Intica Neo 7 DR-T 429558 and Intica Neo 5 DR-T 429568. The supplement sits under the original PMA P000009 because the identifier matches. FDA records the reason as a change to design, components, specifications or materials, and categorizes the products as dual-chamber implantable defibrillators under product code MRM in the cardiovascular specialty.
The only stated purpose in the supplied fields is «the next generation of the Home Monitoring Service Center (HMSC)». That wording does not identify which hardware, software or components changed, what the change affects, or any test results, so those specifics remain absent. The approval covers the supplement, not a fresh approval of the whole system. It documents a regulatory decision, not independent evidence of safety or clinical effectiveness.
FDA approval order statement
the next generation of the Home Monitoring Service Center (HMSC)
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 25, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P000009/S124
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik, Inc.
- Product code
- MRM
- Decision code
- APPR
- Decision date
- Sep 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: DEFIBRILLATOR, IMPLANTABLE, DUAL-CHAMBER.
- Applicant
- Biotronik, Inc.
- Product code
- MRM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P000009. Subsequent supplements may change the device or its indications.
FDA decision timeline
P000009 · Original PMA
PHYLAX AV ICD SYSTEM
P000009/S124 received
Application receipt date recorded by FDA.
P000009/S130 · Related supplement
PSW 2601.U, NEO 2601.U, Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aura DR-T
P000009/S133 · Related supplement
Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aura DR-T, Acticor 7 DR-T, Rivacor 7 DR-T, Rivacor 5 DR-T
P000009/S124 · FDA decision
Normal 180 Day Track
P000009/S132 · Related supplement
Acticor Sky DR-T 481987; Rivacor Sky DR-T 481982; Rivacor Rise DR-T 482018; Rivacor Aura DR-T 482014
P000009/S134 · Related supplement
Intica Neo 7 DR-T DF-1 ProMRI, Intica Neo 5 DR-T DF-1 ProMRI
P000009/S128 · Related supplement
BIOexpress
P000009/S135 · Related supplement
Ilivia Neo 7 DRT, Intica Neo 7 DRT, Intica Neo 5 DRT, Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aur
Timeline entries are records held by MedtechLedger for P000009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P000009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PHYLAX AV ICD SYSTEMP000009 | Biotronik, Inc. | PMA approval | Sep 29, 2000 | FDA |
| Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
BIOexpressP000009/S128 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA |
Explore the linked device profile
Other records with product code MRM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
BIOexpressP050023/S209 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P000009/S124
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




